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Primary sarcomas of the breast are extremely rare, with less than 0.1% of all malignant tumours of the breast. Mayo Clinic Surgical
Pathology database was searched for all breast sarcoma from 1910 to 2000. Pathology reports and slides were reviewed and tumour
types were determined. Metaplastic carcinomas and phyllodes tumours were excluded. There were 25 women ranging in age 24–81
years (mean 45years). All but one patient presented with a palpable lump. Mastectomy was performed in 19 patients and
lumpectomy in five patients. Histopathological diagnoses were fibrosarcoma (six), angiosarcoma (six), pleomorphic sarcoma (six),
leiomyosarcoma (two), myxofibrosarcoma (three), hemangiopericytoma (one) and osteosarcoma (one). Tumour size ranged from
0.3 to 12cm (mean 5.7). Low-grade lesions were observed in 10 cases and high-grade in 15. Overall, mean follow-up was 10.5years.
Local recurrence was observed in 11 patients and ranged from 2 to 36 months (mean 15m), while distant metastasis was observed in
10 patients (40%) affecting lungs, bones, liver, spleen, and skin. Of the 25 patients, 12 have died of disease and six of other causes.
Five-year overall (OS) and cause-specific survival (CSS) were 66 and 70%, respectively. OS and DFS at 5years were 91% for tumours
p5cm and 50% for tumours 45cm. Tumour size was significantly associated with OS (risk ratio¼1.3 per 1cm increase; 95% CI,
1.02–1.7; P¼0.036). There was no significant difference in OS or CSS between low- and high-grade lesions. In this series, tumour
size was a more valuable prognostic factor than tumour grade.
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Primary sarcomas of the breast are rare, malignant tumours
arising from the mesenchymal tissue of the mammary gland
(Oberman, 1965; Barnes and Pietruszka, 1977; Callery et al, 1985),
with an approximate incidence of 17 new cases per million women
(Moore and Kinne, 1996). At the Mayo Clinic, 27881 malignant
breast tumours were seen between 1940 and 1999 (C Adem,
personal unpublished data) and 18 breast sarcomas were
diagnosed accounting for 0.0006% of breast malignancies.
Breast sarcomas should be distinguished from metaplastic
carcinomas (Adem et al, 2002). When facing a spindle cell
neoplasm in an epithelial organ such as the breast one should be
careful in rendering the diagnosis of sarcoma. In this setting,
immunohistochemistry using the right antibodies is of major
input. Berg et al defined stromal sarcomas of the breast in 1962 as
a group of mesenchymal malignant tumours with fibrous, myxoid
and adipose components, excluding malignant cystosarcoma
phyllodes, lymphomas and angiosarcomas (Berg et al, 1962).
However, series in the literature have included many different
entities under the rubric of sarcomas such as cystosarcoma
phyllodes, lymphosarcoma and carcinosarcoma (Botham et al,
1958; Donegan, 1967; Fawcett, 1967; Kennedy and Biggart, 1967;
Rissanen and Holsti, 1968; Gogas et al, 1976; Ludgate et al, 1977;
Khanna et al, 1981; Christensen et al, 1988; Terrier et al, 1989; Pitts
et al, 1991; Ciatto et al, 1992; Luna Vega et al, 1992; McGregor et al,
1994; Moore and Kinne, 1996; McGowan et al, 2000). For this
review, we choose to categorise primary breast sarcomas in
histogenic terms, similar to other soft-tissue sarcomas, thus
including angiosarcomas, and excluding malignant cystosarcomas
phyllodes, as reported by others (see Table 1) (Berg et al, 1962;
Oberman, 1965; Norris and Taylor, 1968; Barnes and Pietruszka,
1977; Callery et al, 1985; Stanley et al, 1988; Pollard et al, 1990;
Johnstone et al, 1993; Smola et al, 1993; Gutman et al, 1994; North
et al, 1998; Barrow et al, 1999).
MATERIALS AND METHODS
All cases diagnosed pathologically at our institution from 1910 to
2000 as breast sarcomas and stromal sarcomas were retrieved from
Mayo Clinic Surgical Pathology files.
The H&E-stained sections were examined in all cases to confirm
the diagnosis. An average of seven (range, 1–28) H&E slides per
case were available. Clinical charts and surgical notes were
retrospectively reviewed and the following information was
collected: age, gender, size of tumour, clinical presentation,
duration of symptom, history of radiation, type of surgery, local
recurrences and systemic metastases. Follow-up information was
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lobtained from patient records and death certificates. Patients with
other prior primary malignancy in the breast, radiation therapy
and metastatic disease to the breast were excluded.
Patients with cystosarcoma phyllodes were excluded, as well as
patients with metaplastic carcinoma. For this purpose, immunoper-
oxidase studies were performed using two primary antibodies,
vimentin, to determine immunocompetence and wide spectrum
screening keratin, to diagnose a metaplastic carcinoma as reported
earlier (Adem et al, 2002). In regards of the fact that some cases
were diagnosed at the beginning of the century, if immunoperox-
idase study with vimentin was negative, another block representa-
tive of the tumour was chosen for further immunostaining. If
vimentin staining was still negative, search for an internal control
such as normal or carcinomatous component was done in each case.
Size, diagnosis, infiltrative or nodular pattern, presence of
heterologous elements, grade according to Broders’ scheme of
grading used at the Mayo Clinic, mitotic index (in 10 high-power
fields, using a Leitz microscope, field diameter 0.45mm), and
necrosis were assessed.
Overall survival (OS) and cause-specific survival (CSS) following
diagnosis were estimated based on the Kaplan–Meier method,
overall and separately for morphological features. Associations
between morphologic features and survival were evaluated
univariately based on fitting Cox proportional hazards models.
All calculated P-values were two-sided and P-values less than 0.05
were considered statistically significant.
RESULTS
In all, 42 patients were retrieved between 1910 and 2000. Six were
excluded after morphological review for the following reasons:
cystosarcoma phyllodes (n¼4), fibromatosis (n¼1), benign
haemangioma (n¼1). Totally, 11 cases were also excluded after
showing a positive stain with wide spectrum screening keratin, and
being considered metaplastic carcinoma.
Clinical data
Overall, 25 remaining patients constituted the study group and are
summarised in Table 2. There were 25 women age range 24–81
(mean 45 years). In total, 24 cases presented with lump, two of
them associated with pain. In one case, it presented as an
incidental mammographic finding. Contralateral breast sarcoma
had been diagnosed elsewhere 3 years earlier in one case, renal cell
carcinoma 5 years later in one case, colon cancer 4 years earlier in
one case, skin melanoma and uterine cancer in one case 16 and 27
years earlier, respectively. No history of prior radiation was found
in any case, therefore excluding postradiation sarcoma. The
duration of symptoms for 16 patients ranged between 1 month
to 40 years (mean 3.2 years).
Surgical treatment was excision in five cases, mastectomy in 19
cases (modified, four; simple, five; radical, five; not specified, five),
and unknown in one case. Adjuvant therapy was administered in
five cases (radiation, four; chemotherapy, one).
The right breast was affected in 10 cases, while the left was
affected in 15 cases.
Pathological data
Gross description was available in 12 cases. Eight tumours were
described as well-circumscribed, four as infiltrative of which two
were angiosarcoma. Tumour size was available on 18 patients, and
the mean tumour size was 5.7cm (range 0.3–12.0). Angiosarcomas
tended to be larger in size with a mean of 10cm (range, 8–12cm).
After present review, histopathological diagnoses were fibrosar-
coma (n¼6), angiosarcoma (n¼6), pleomorphic sarcoma (n¼6),
leiomyosarcoma (n¼2), myxofibrosarcoma (n¼3), hemangioper-
icytoma (n¼1) and osteosarcoma (n¼1). Tumours were graded
as low grade (grade 1, one; grade 2, nine), and high grade (grade 3,
seven; grade 4, eight). Necrosis was observed in four cases (three
high-grade tumours). In all, 11 (range, 0–43) mitoses were found
on average in 10 HPF. Heterologous component was seen in one
case of osteosarcoma. Seven had pushing margins while 16 had
infiltrative ones.
An in situ ductal carcinoma component was observed in one
case. In this case of pleomorphic sarcoma, keratin staining was
negative in neoplastic cells with adequate internal control (the in
situ component as well as benign entrapped ducts).
There was no metastasis in the 15 cases where axillary node
dissection was performed.
Table 1 Major breast sarcomas comparable series in the English literature
Author
N cases/
period
Median age
(years)
Median size
(cm) Diagnosis Prognostic factors
Barnes and Pietruszka (1977) 10/31years 51 6.3 5F, 1RMS, 1Le, 2OGS, 1 Li Tumour contour, atypia, mitosis
Barrow et al (1999) 59/43years 45 UK 32F, 17A, 1OGS, 7 NOS Size, margins status, type
Berg et al (1962) 25/UK 48 6.0 Li and F Positive margins
Callery et al (1985) 25/33years 54 4.0 9F, 5M, 1HPC, 2Le, 2D,
3Desmoid, 1Li, 2 SS
UK
Gutman et al (1994) 60/51years 48 6.5 17A, 16SS, 10F, 6M, 3O, 2Li,
2Le, 1R, 3U
Size, multifocal lesions, vascular,
lymphatic, skin or chest wall invasion
Johnstone et al (1993) 10/12years 28 UK 4A, 2M, 1R, 1Li, 1SS, 1Sc UK
Norris and Taylor (1968) 32/UK 49 4.0 5 OGS, 1 Le/R, 3 Li, 1D, 22F Size, contour, atypia, mitotic activity
North et al (1998) 25/31years 55 6.0 10A, 5SS, 3F, 2Li, 2Le, 1M,
1OGS, 1 U
Type of surgery
Oberman (1965) 13/30y 56 7.1 7f, 3R, 2D, 1MM Size, type of surgery
Pollard et al (1990) 25/81years 55.4 5.9 11M, 6Li, 4F, 1CC, 1NS, 1Le,
1ASP
Type of surgery
Smola et al (1993) 8/23years 56 12.8 2CHS, 1M, 2Li, 2F, 1A UK
Stanley et al (1988) 4/UK 61 UK 2M, 2A UK
Zelek et al (2003) 83/37years 47 6.5 58M, 8A, 7L, 2Sc, 2R, 2OGS,
2Le, 2O
Grade, size
A ¼ angiosarcoma; SS ¼ stromal sarcoma; F ¼ fibrosarcoma; M ¼ malignant fibrous histiocytoma; Li ¼ liposarcoma; D ¼ dermatofibrosarcoma protuberans; Sc ¼ spindle
cell sarcoma; Cs ¼ carcinosarcoma; Le ¼ leiomyosarcoma; R ¼ rhabdomyosarcoma; U ¼ unspecified; CC ¼ clear cell sarcoma; ASP ¼ alveolar soft part sarcoma; MM ¼
malignant mesenchymoma; OGS ¼ osteosarcoma; Others ¼ O.
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lFollow-up and survival analysis (Figure 1)
Overall mean and median follow-up were, respectively, 10.5 and
6.4 years (range, 7 months–41 years). Local recurrence was
observed in 11 patients and ranged from 2 to 36 months (mean 15
months), while distant metastasis was observed in 10 patients, in
order of frequency affecting the lungs (n¼7), bones (n¼6), liver
(n¼5), spleen (two) and skin (two). In one case, other sites were
also kidney, pancreas, adrenal, omentum, epicardium and
mediastinum. Of the 25 patients, 12 have died of disease and six
of other causes. At the last follow-up, seven patients were still alive
with a mean and median follow-up of 10.2 and 10.9 years,
respectively.
Table 2 Patients clinical and pathological characteristics in our series
Age
(years) Diagnosis Duration Surgery
Adjuvant
therapy Size Gross Margins Grade
Local
recurrence Metastases Last follow-up
Case 1 38 MXFS 15m R Mast N UK C N 2 3y, S N DUK,
45m
Case 2 38 F UK R Mast RT 5 UK UK 2 N N DOC,
5.5y
Case 3 31 PS 2m Excision N UK UK I 4 1y, R Mast N DOC,
1y
Case 4 38 A UK Excision N UK UK I 2 5 times,
3t o6y ,
S/RT
L, 6y DOD,
84m
Case 5 72 PS UK R Mast N 3 I I 4 N N Alive,
18y
Case 6 49 F 1m Mast UK 3 UK I 3 N N DOC,
37y
Case 7 43 A 1m Mast N 8 C I 1 N B/L, 1y, S/CT DOD,
16m
Case 8 48 MXFS 96m Mast RT 5.5 I I 3 4m, No TTT N AWD,
6m
Case 9 55 F 2m Mast UK UK UK N 2 Twice,
11m and
17m, S
N DOD,
76m
Case 10 67 Le UK Excision CT 2 UK UK 4 N Li/B/Skin, at presentation, CT DOD,
7m
Case 11 39 A 2m Excision N 8 I I 2 20m, S Li/Jejunum, 9y, None DOD,
114m
Case 12 32 PS 2m Excision N UK UK I 4 2m, S N DOD,
23m
Case 13 52 F 4m M R Mast N 4.5 C I 3 N N Alive,
NED,
23.5y
Case 14 27 A 11m S Mast N 12 I I 2 11m, UK L/Li/S, 22m, UK DOD,
32m
Case 15 63 MXFS 30y S Mast N 4 C N 2 N N DOC,
21y
Case 16 60 PS 12m R Mast RT 10 C N 4 N B/Lu, 6y, RT DOD,
88m
Case 17 55 Le UK Mast N 4 UK N 4 N Multiple sites, 6y, CT DOD,
77m
Case 18 33 A 12m R Mast RT 10 C I 2 10m, UK B, 10m, RT DOD,
13m
Case 19 33 HPC UK UK UK UK UK N 4 N L/Li/Pelvis, UK, RT DOD,
41m
Case 20 24 PS 12 S Mast N 5 C I 3 N N Alive,
NED,
11y
Case 21 32 A 11m S Mast N UK UK I 3 14m, RT B/L, 14m, RT/CT DOD,
26m
Case 22 42 F UK S Mast N 3 UK I 3 8m, S N DOC,
49y
Case 23 54 F 1m M R Mast N 5 UK N 2 N N Alive,
NED,
13y
Case 24 81 PS UK M R Mast N 0.3 UK I 4 N N Alive,
NED,
14m
Case 25 54 OGS UK M R Mast N 10 C I 3 N N Alive,
NED,
4y
Abbreviations: MXFS ¼ myxofibrosarcoma; F ¼ fibrosarcoma; PS ¼ pleomorphic sarcoma; AGS ¼ angiosarcoma; Le ¼ leiomyosarcoma; HPC ¼ hemangiopericytoma; OGS
¼ osteosarcoma; UK ¼ unknown; R ¼ radical; Mast ¼ mastectomy; S ¼ simple; M ¼ modified; RT ¼ radiotherapy; CT ¼ chemotherapy; C ¼ circumscribed; I ¼
infiltrative; y ¼ year; m ¼ month; DOC ¼ dead of other causes; DUK ¼ dead of unknown cause; NED ¼ no evidence of disease; DOD ¼ dead of disease; Lu ¼ lung; B ¼
bone; Li ¼ liver; S ¼ spleen; N ¼ nodular or pushing margins; I ¼ infiltrative.
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and 70%, respectively. Five-year OS and CSS were both 91% for
tumours p5cm, and 50% for tumours 45cm. Tumour size was
significantly associated with OS (risk ratio¼1.3 per 1cm increase;
95% CI, 1.02–1.7; P¼0.036). There was no significant difference
between low- and high-grade lesions (OS were 60 and 70%,
P¼0.14, CSS were 70 and 70%, P¼0.5, respectively) or tumours
showing infiltrative compared to pushing margins (OS were 65 and
71%, P¼0.47, CSS were 65 and 86%, P¼0.94, respectively) in
terms of OS or CSS.
Although there was no statistically significant association
between tumour size and metastasis or recurrence, mean tumour
size of patients with recurrence or metastasis was 7.7cm,
compared to 4.9 and 4.3cm, respectively, for patients without
recurrence or metastasis. Four out of five patients treated with
simple excision had recurrence or metastasis.
By the most common histopathologic types, all but one patient
with angiosarcoma (4/5), one patient with fibrosarcoma, and two
patients with pleomorphic sarcoma, died of disease.
DISCUSSION
Primary breast sarcomas are extremely rare (Moore and Kinne,
1996). In our institution, they compose 0.0006% of breast
malignancies. They constitute a specific clinicopathologic entity
and, therefore should be differentiated from the two main entities
in differential diagnosis, cystosarcoma phyllodes and metaplastic
carcinoma. Specific morphological features (biphasic tumour, with
leaf-like architecture and epithelial component) recognise the
former, and extensive sampling of the tumour can help when a
stromal overgrowth is present. The latter is recognised on H&E
sections by the presence of a carcinomatous component, or based
on a cytokeratin immunopositivity of the neoplastic spindle cells.
Reported series in the English literature had included all three
entities as breast sarcomas, and include in their reports
angiosarcomas, desmoid tumours, and lymphosarcomas (Botham
et al, 1958; Berg et al, 1962; Oberman, 1965; Donegan, 1967;
Fawcett, 1967; Kennedy and Biggart, 1967; Norris and Taylor, 1968;
Rissanen and Holsti, 1968; Gogas et al, 1976; Barnes and
Pietruszka, 1977; Ludgate et al, 1977; Khanna et al, 1981; Callery
et al, 1985; Christensen et al, 1988; Stanley et al, 1988; Terrier et al,
1989; Pollard et al, 1990; Pitts et al, 1991; Ciatto et al, 1992;
Luna Vega et al, 1992; Johnstone et al, 1993; Smola et al, 1993;
Gutman et al, 1994; McGregor et al, 1994; Moore and Kinne, 1996;
North et al, 1998; Barrow et al, 1999; McGowan et al, 2000).
Therefore, reliable assessments of prognostic factors are difficult
to make based on the published literature. Table 1 depicts
comparable major series using soft-tissue tumours as basis
for classification.
Tumour size seems to be the most frequently reliable prognostic
factor in many of these series, as in breast carcinomas and soft-
tissue sarcomas (Oberman, 1965; Norris and Taylor, 1968; Gutman
et al, 1994; Barrow et al, 1999; Zelek et al, 2003) Other reported
prognostic factors are the histopathological diagnosis (Barrow et al,
1999), the infiltrative features (Norris and Taylor, 1968; Barnes and
Pietruszka, 1977), the histopathologic grading (Norris and Taylor,
1968; Barnes and Pietruszka, 1977; Gutman et al, 1994; Barrow et al,
1999; Zelek et al, 2003), presence of positive margins (Berg et al,
1962; Barrow et al, 1999), and extent of surgery for local recurrence
(Pollard et al, 1990; North et al, 1998). Some authors found age to
be of prognostic importance (Ludgate et al, 1977). Margins status
is a major risk factor for recurrence as it occurs in any neoplastic
entity, and some authors advised adjuvant radiotherapy for cases
with positive margins (Callery et al, 1985; Smola et al, 1993), or
less than 2cm of clear margins (McGowan et al, 2000). Treatment
is generally based on a wide local excision, without axillary
dissection (Barrow et al, 1999). Breast sarcomas bear different
histogenesis than breast carcinomas as shown by cytogenetic
studies (Garcia-Palazzo et al, 1992), and biological behaviour (Berg
et al, 1962).
We believe that breast sarcomas are comparable to soft-tissue
sarcomas seen elsewhere. They present mainly as a lump and size
is a prognostic marker with 5cm serving as a valuable cut point.
Tumour grade did not correlate with the outcome in our series but
statistical power was limited and this finding could be related to
the small size of the series. Lymphatic spread is uncommon as
shown by the absence of axillary lymph node metastasis in our
cases, and therefore axillary node dissection is not necessary.
When lymph node metastasis is present, the diagnosis of a
metaplastic carcinoma should be considered even in the presence
of a pure spindle cell neoplasm.
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